Health Care
Commentary
Moderna, Pfizer signal they plan to raise price of their shots
In defense of pandemic profits
The price of a COVID-19 shot will soon go up. The federal public health emergency ended this month, and the government will stop providing COVID vaccines to all Americans free of charge. Moderna and Pfizer have both signaled that they plan to raise the prices of their shots once the ...
Commentary
Read the most recent update on the COVID public health emergency
Why is Medicaid still treating COVID-19 as a public health emergency?
The federal public health emergency for the COVID-19 pandemic came to an end Thursday, more than three years after it was first enacted in 2020. That comes on the heels of the World Health Organization’s declaration on May 5 that COVID-19 was no longer a global health emergency. And on ...
Commentary
Medicaid Work Requirements Address Laziness Head On
The spending cuts included in the bill House Republicans passed in late April to raise the debt ceiling have Democrats up in arms. But federal spending has soared. It’s now 5 percentage points higher as a share of GDP than the average since 1960. As House Speaker Kevin McCarthy quipped this week, “Is it ...
Commentary
Read latest on drug pricing
The Continuing Danger From Progressive’s Faulty Excess Profit Allegations
Sen. Bernie Sanders (D-Vermont) and Rep. Alexandria Ocasio-Cortez (D-New York) continuously confirm Alexander Pope’s famous maxim about a little bit of knowledge. It truly is a dangerous thing, especially in the hands of politicians. During a May 11th meeting of the Senate Health, Education, Labor and Pensions (HELP) committee, Sen. ...
Commentary
Today's commentary on pharmaceutical benefit managers
Will Senate Hearing Expose PBMs’ Unscrupulous Drug Pricing Tactics?
Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on “the need to make insulin affordable for all Americans.” Sen. Sanders is sure to call the pharmaceutical executives — ...
Commentary
Thank the IRA for Cuts to Critical Drug Research
President Biden’s Inflation Reduction Act is just eight months old. It hasn’t yet slayed inflation. But it’s already gutting drug research and development. The law gives Medicare the power to impose price controls on certain prescription drugs for the first time. By September, federal officials will select the first 10 ...
Commentary
Small-Molecule Price Controls Are A Big Mistake
The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly ...
Commentary
Democrats want a fully socialized healthcare system
The Inflation Reduction Act Was Only The Beginning
As it turns out, the fears that the Inflation Reduction Act (IRA) was simply another step toward a fully socialized healthcare system were well founded. For evidence, less than a year after the IRA was signed into law U.S. Senators Amy Klobuchar (D-MN), Peter Welch (D-VT) and 23 Democrat colleagues ...
Commentary
Read about Biden's latest policy proposal
Time for Hospitals to Come Clean About Pricing
The Biden administration is cracking down on hospitals that keep their prices secret. Under a policy announced last week, failing to abide by Trump-era hospital price transparency rules will no longer prompt a warning letter from the Centers for Medicare and Medicaid Services. Instead, hospitals will have 45 days to ...
Drug Innovation
Wayne Winegarden on NTD News to Discuss Congress Pushing Back on Pharmaceutical Benefit Managers
Congress is beginning to push back on pharmaceutical benefit managers (PBMs). PRI’s Wayne Winegarden tells NTD News that a large problem lies in the lack of transparency in the drug pricing system. Reforming the PBM system could reduce costs for patients. Click to watch the interview on NTD News.
Moderna, Pfizer signal they plan to raise price of their shots
In defense of pandemic profits
The price of a COVID-19 shot will soon go up. The federal public health emergency ended this month, and the government will stop providing COVID vaccines to all Americans free of charge. Moderna and Pfizer have both signaled that they plan to raise the prices of their shots once the ...
Read the most recent update on the COVID public health emergency
Why is Medicaid still treating COVID-19 as a public health emergency?
The federal public health emergency for the COVID-19 pandemic came to an end Thursday, more than three years after it was first enacted in 2020. That comes on the heels of the World Health Organization’s declaration on May 5 that COVID-19 was no longer a global health emergency. And on ...
Medicaid Work Requirements Address Laziness Head On
The spending cuts included in the bill House Republicans passed in late April to raise the debt ceiling have Democrats up in arms. But federal spending has soared. It’s now 5 percentage points higher as a share of GDP than the average since 1960. As House Speaker Kevin McCarthy quipped this week, “Is it ...
Read latest on drug pricing
The Continuing Danger From Progressive’s Faulty Excess Profit Allegations
Sen. Bernie Sanders (D-Vermont) and Rep. Alexandria Ocasio-Cortez (D-New York) continuously confirm Alexander Pope’s famous maxim about a little bit of knowledge. It truly is a dangerous thing, especially in the hands of politicians. During a May 11th meeting of the Senate Health, Education, Labor and Pensions (HELP) committee, Sen. ...
Today's commentary on pharmaceutical benefit managers
Will Senate Hearing Expose PBMs’ Unscrupulous Drug Pricing Tactics?
Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on “the need to make insulin affordable for all Americans.” Sen. Sanders is sure to call the pharmaceutical executives — ...
Thank the IRA for Cuts to Critical Drug Research
President Biden’s Inflation Reduction Act is just eight months old. It hasn’t yet slayed inflation. But it’s already gutting drug research and development. The law gives Medicare the power to impose price controls on certain prescription drugs for the first time. By September, federal officials will select the first 10 ...
Small-Molecule Price Controls Are A Big Mistake
The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly ...
Democrats want a fully socialized healthcare system
The Inflation Reduction Act Was Only The Beginning
As it turns out, the fears that the Inflation Reduction Act (IRA) was simply another step toward a fully socialized healthcare system were well founded. For evidence, less than a year after the IRA was signed into law U.S. Senators Amy Klobuchar (D-MN), Peter Welch (D-VT) and 23 Democrat colleagues ...
Read about Biden's latest policy proposal
Time for Hospitals to Come Clean About Pricing
The Biden administration is cracking down on hospitals that keep their prices secret. Under a policy announced last week, failing to abide by Trump-era hospital price transparency rules will no longer prompt a warning letter from the Centers for Medicare and Medicaid Services. Instead, hospitals will have 45 days to ...
Wayne Winegarden on NTD News to Discuss Congress Pushing Back on Pharmaceutical Benefit Managers
Congress is beginning to push back on pharmaceutical benefit managers (PBMs). PRI’s Wayne Winegarden tells NTD News that a large problem lies in the lack of transparency in the drug pricing system. Reforming the PBM system could reduce costs for patients. Click to watch the interview on NTD News.
